Modeling Tumor Growth and Treatment Resistance Dynamics Characterizes Different Response to Gefitinib or Chemotherapy in Non‐Small Cell Lung Cancer

por Nagase, Mario, Aksenov, Sergey, Yan, Hong, Dunyak, James, Al‐Huniti, Nidal
Publicado 2020

Resistance models to EGFR inhibition and chemotherapy in non-small cell lung cancer via analysis of tumour size dynamics

por Mistry, Hitesh B., Helmlinger, Gabriel, Al-Huniti, Nidal, Vishwanathan, Karthick, Yates, James
Publicado 2019

Population Exposure‐Response Modeling Supported Selection of Naloxegol Doses in Phase III Studies in Patients With Opioid‐Induced Constipation

por Al‐Huniti, Nidal, Xu, Hongmei, Zhou, Diansong, Aksenov, Sergey, Fox, Robert, Bui, Khanh H.
Publicado 2017

Population pharmacokinetics and exposure–response modeling for evinacumab in homozygous familial hypercholesterolemia

por Pu, Xia, Sale, Mark, Yang, Feng, Zhang, Yi, Davis, John D., Al‐Huniti, Nidal
Publicado 2021

Tumor Growth Dynamic Modeling in Oncology Drug Development and Regulatory Approval: Past, Present, and Future Opportunities

por Al‐Huniti, Nidal, Feng, Yan, Yu, Jingyu (Jerry), Lu, Zheng, Nagase, Mario, Zhou, Diansong, Sheng, Jennifer
Publicado 2020

Population pharmacokinetics modeling and exposure‐response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer

por Nguyen, Jenny‐Hoa, Epling, Daniel, Dolphin, Nancy, Paccaly, Anne, Conrado, Daniela, Davis, John D., Al‐Huniti, Nidal
Publicado 2022

Evaluation of the Drug–Drug Interaction Potential of Acalabrutinib and Its Active Metabolite, ACP‐5862, Using a Physiologically‐Based Pharmacokinetic Modeling Approach

por Zhou, Diansong, Podoll, Terry, Xu, Yan, Moorthy, Ganesh, Vishwanathan, Karthick, Ware, Joseph, Slatter, J. Greg, Al‐Huniti, Nidal
Publicado 2019

Reporting guidelines for population pharmacokinetic analyses

por Dykstra, Kevin, Mehrotra, Nitin, Tornøe, Christoffer Wenzel, Kastrissios, Helen, Patel, Bela, Al-Huniti, Nidal, Jadhav, Pravin, Wang, Yaning, Byon, Wonkyung
Publicado 2015

A quantitative systems pharmacology modeling platform for evaluating triglyceride profiles in patients with high triglycerides receiving evinacumab

por Khaksar Toroghi, Masood, Bosley, Jim, Powell, Lyn M., Zhang, Yi, Yang, Feng, Pu, Xia, Davis, John D., Al‐Huniti, Nidal
Publicado 2021

Radiation and PD-(L)1 treatment combinations: immune response and dose optimization via a predictive systems model

por Kosinsky, Yuri, Dovedi, Simon J., Peskov, Kirill, Voronova, Veronika, Chu, Lulu, Tomkinson, Helen, Al-Huniti, Nidal, Stanski, Donald R., Helmlinger, Gabriel
Publicado 2018

Getting Innovative Therapies Faster to Patients at the Right Dose: Impact of Quantitative Pharmacology Towards First Registration and Expanding Therapeutic Use

por Nayak, Satyaprakash, Sander, Oliver, Al‐Huniti, Nidal, de Alwis, Dinesh, Chain, Anne, Chenel, Marylore, Sunkaraneni, Soujanya, Agrawal, Shruti, Gupta, Neeraj, Visser, Sandra A.G.
Publicado 2018

A drug‐disease model for predicting survival in an Ebola outbreak

por Toroghi, Masood Khaksar, Al‐Huniti, Nidal, Davis, John D., DiCioccio, A. Thomas, Rippley, Ronda, Baum, Alina, Kyratsous, Christos A., Sivapalasingam, Sumathi, Kantrowitz, Joel, Kamal, Mohamed A.
Publicado 2022

The Posology of Dupilumab in Pediatric Patients With Atopic Dermatitis

por Kamal, Mohamed A., Kovalenko, Pavel, Kosloski, Matthew P., Srinivasan, Kamal, Zhang, Yi, Rajadhyaksha, Manoj, Lai, Ching‐Ha, Kanamaluru, Vanaja, Xu, Christine, Sun, Xian, Simpson, Eric L., Paller, Amy S., Siegfried, Elaine C., Shumel, Brad, Bansal, Ashish, Al‐Huniti, Nidal, Davis, John D.
Publicado 2021

Assessing the Combined Public Health Impact of Pharmaceutical Interventions on Pandemic Transmission and Mortality: An Example in SARS CoV‐2

por Kamal, Mohamed A., Kuznik, Andreas, Qi, Luyuan, Więcek, Witold, Hussein, Mohamed, Hassan, Hazem E., Patel, Kashyap, Obadia, Thomas, Toroghi, Masood Khaksar, Conrado, Daniela J., Al‐Huniti, Nidal, Casciano, Roman, O'Brien, Meagan P., Barnabas, Ruanne V., Cohen, Myron S., Smith, Patrick F.
Publicado 2022